- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02480998
Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults
A Randomized, Double-blind, Active Comparator, Phase I/Ⅱa Clinical Trial to Assess the Safety and Immunogenicity of the 'IL-YANG Flu Vaccine Quadrivalent Inj.' in Healthy Korean Adult Subjects
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a randomized, double-blind, active-controlled, phase I/Ⅱa clinical trial.
During the Part A phase, all safety data collected from the 12 subjects enrolled in the Part A phase will be analyzed to determine the safety and tolerability of the investigational product, which should include any solicited and unsolicited adverse drug reactions occurring for the first 7 days after vaccination and any adverse events occurring for 28 days after vaccination. Antibody titer test will be also performed to evaluate the efficacy (immunogenicity) of the investigational product. During the Part B phase, a total of 72 subjects will be enrolled, and all safety data (including all adverse events) and immunogenicity data will be analyzed.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 1
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Healthy men and women 19 to < 65 years of age at screening
- Body weight within ±20% of ideal body weight at screening
- Women of childbearing potential must have a negative serum beta-hCG at visit 2; and agree to use a proper contraceptive method for 1 month after vaccination (starting from 3 months before screening), using a medication or device that does not have any drug-interaction with the investigational product.
- Subjects with no congenital or chronic disease who were considered suitable for the study after screening assessments (investigator's opinion, medical history, physical examination, laboratory test, chest X-ray, and ECG) conducted no later than 28 days prior to vaccination
- Subjects who were given, and fully understood, the information about the study, and have provided voluntary written informed consent to participate in the study and to comply with all applicable study requirements
Exclusion Criteria:
- Subject with known allergy to eggs, chicken, or any components of the investigational product
- Subjects who had received an influenza vaccine within the last 6 months prior to study entry
- Subjects who have known or suspected infection with HAV, HBV, HCV, HIV or VDRL
- Subjects who have concurrent or a past history of, immune deficiency disease
- Subject with a history of Guillain-Barre syndrome
- Subject with hemophilia or thrombocytopenia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection
- Subjects with known allergy to a drug, food or latex, who had a history of anaphylaxis
- Subjects who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the investigational product or symptoms of suspected acute disease within 14 days prior to administration of the investigational product
- Subjects who had received another vaccine within 28 days before administration of the investigational product or are planning to receive another vaccine during the study.
- Subjects who had participated in another clinical trial within the 30 days before administration of the investigational product.
- Subjects who had previously received blood-derived products (including immunoglobulin) within the last 3 months prior to administration of the Investigational product, or are scheduled to receive a treatment with blood-derived products during the study
- Subjects who had received, or are scheduled to receive, systemic immunosuppressive therapy, radiation therapy or high-dose steroid therapy within the last 6 months prior to administration of the study
- Subjects with a history of drug abuse within the last 6 months prior to vaccination, or is suspected of drug abuse
- Subjects with excessive consumption of caffeine, alcohol, or tobacco
- Subjects with other clinically significant medical or psychiatric illness who in the investigator's opinion, are not be suitable for the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: IL-YANG Flu Vaccine QIV 0.5mL
A single 0.5mL dose administrated as an intramuscular injection.
|
|
Aktiv komparator: IL-YANG Flu Vaccine TIV 0.5mL
A single 0.5mL dose administrated as an intramuscular injection.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Seroconversion Rate
Tidsramme: 28 days
|
Percentage of subjects achieving seroconversion* for HI antibody after vaccination
|
28 days
|
Seroprotection Rate
Tidsramme: 28 days
|
Percentage of subjects achieving seroprotection* for HI antibody after vaccination
|
28 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
GMR
Tidsramme: 28 days
|
Geometric Mean Ratio of post vaccination HI geometric mean titers
|
28 days
|
GMT
Tidsramme: 28 days
|
Geometric Mean Titer of post vaccination HI geometric mean titers
|
28 days
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IY_IFEZ_Q120
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Influensa, menneske
-
Center for Social Innovation, MassachusettsColumbia University; Hunter College of City University of New YorkFullførtHjemløsetjenester | Human Services TrainingForente stater
-
USDA, Western Human Nutrition Research CenterUniversity of Copenhagen; Bill and Melinda Gates Foundation; International... og andre samarbeidspartnereRekrutteringHuman Milk Nutrient Reference VerdierDanmark, Bangladesh, Brasil, Gambia
-
Washington University School of MedicineMerck Sharp & Dohme LLCTilbaketrukketHuman T-celle Leukemi Virus Type 1 Infeksjon
-
Nutricia ResearchAktiv, ikke rekrutterendeVekst | Toleranse | Sikkerhet | Emner som trenger en Human Milk Fortifier (HMF)Nederland, Frankrike, Tyskland, Storbritannia
-
Guangdong Academy of Medical SciencesGuangzhou First People's Hospital; Guangzhou General Hospital of Guangzhou... og andre samarbeidspartnereUkjentHuman epidermal vekstfaktor 2 negativt brystkarsinomKina
-
Qingdao Central HospitalFullførtHuman epidermal vekstfaktor 2 negativt brystkarsinomKina
-
BiocadFullførtHuman epitelreseptor (HER)-2 positiv brystkreftUkraina, Den russiske føderasjonen, Hviterussland, India
-
Jinling Hospital, ChinaUkjentCrohns sykdom | Metylering | Illumina Human Methylation 850k BeadChipKina
-
Istituto Scientifico Romagnolo per lo Studio e...FullførtHuman epidermal vekstfaktor 2 negativt brystkarsinomItalia
-
ModernaTX, Inc.FullførtHumant metapneumovirus og human parainfluensainfeksjonForente stater
Kliniske studier på IL-YANG Flu Vaccine QIV 0.5mL
-
Il-Yang Pharm. Co., Ltd.Fullført
-
Il-Yang Pharm. Co., Ltd.Fullført
-
Il-Yang Pharm. Co., Ltd.Har ikke rekruttert ennå
-
Il-Yang Pharm. Co., Ltd.Fullført